Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting

Journal of Immunology

Volumn 185, Issue 10, 2010, Pages 5869-5878

  Cohen, Merav ^a   Elkabets, Moshe ^a   Perlmutter, Michal ^a   Porgador, Angel ^a   Voronov, Elena ^a   Apte, Ron N ^a   Lichtenstein, Rachel G ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; GAMMA INTERFERON; NATURAL KILLER CELL RECEPTOR NKG2D; SIALIC ACID; SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; FIBROSARCOMA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOEDITING; IMMUNOGENICITY; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIALYLATION; TUMOR CELL; WILD TYPE;

ANIMALS; CARCINOGENS; CELL PROLIFERATION; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; KILLER CELLS, NATURAL; METHYLCHOLANTHRENE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; N-ACETYLNEURAMINIC ACID; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 78650663362     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001635     Document Type: Review

References (50)

1. Varki, A. 2007. Glycan-based interactions involving vertebrate sialic-acidrecognizing proteins. Nature 446:1023-1029.
2. Fuster, M. M., and J. D. Esko. 2005. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5:526-542.
3. Hedlund, M., E. Ng, A. Varki, and N. M. Varki. 2008. alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res. 68:388-394.
4. Varki, N. M., and A. Varki. 2007. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab. Invest. 87:851-857.
5. Hakomori, S. 1996. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res. 56:5309-5318.
6. Wölfl, M., W. Y. Batten, C. Posovszky, H. Bernhard, and F. Berthold. 2002. Gangliosides inhibit the development from monocytes to dendritic cells. Clin. Exp. Immunol. 130:441-448.
7. Miyazaki, K., K. Ohmori, M. Izawa, T. Koike, K. Kumamoto, K. Furukawa, T. Ando, M. Kiso, T. Yamaji, Y. Hashimoto, et al. 2004. Loss of disialyl Lewis (a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulinlike lectin-7 (Siglec-7) associated with increased sialyl Lewis (a) expression on human colon cancers. Cancer Res. 64:4498-4505.
8. von Gunten, S., and H. U. Simon. 2006. Sialic acid binding immunoglobulin-like lectins may regulate innate immune responses by modulating the life span of granulocytes. FASEB J. 20:601-605.
9. Aarnoudse, C. A., J. J. Garcia Vallejo, E. Saeland, and Y. van Kooyk. 2006. Recognition of tumor glycans by antigen-presenting cells. Curr. Opin. Immunol. 18:105-111.
10. Kopitz, J., C. von Reitzenstein, M. Burchert, M. Cantz, and H. J. Gabius. 1998. Galectin-1 is a major receptor for ganglioside GM1, a product of the growthcontrolling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture. J. Biol. Chem. 273:11205-11211.
11. van Kooyk, Y., and G. A. Rabinovich. 2008. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9:593-601.
12. Dunn, G. P., C. M. Koebel, and R. D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6:836-848.
13. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148.
14. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-1111.
15. Smyth, M. J., G. P. Dunn, and R. D. Schreiber. 2006. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90:1-50.
16. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
17. Zitvogel, L., A. Tesniere, and G. Kroemer. 2006. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6:715-727.
18. Elkabets, M., Y. Krelin, S. Dotan, A. Cerwenka, A. Porgador, R. G. Lichtenstein, M. R. White, M. Zoller, Y. Iwakura, C. A. Dinarello, et al. 2009. Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells. J. Immunol. 182:4874-4881.
19. Avidan, A., M. Perlmutter, S. Tal, O. Oraki, T. Kapp, Y. Krelin, M. Elkabets, S. Dotan, R. N. Apte, and R. G. Lichtenstein. 2009. Differences in the sialylation patterns of membrane stress proteins in chemical carcinogen-induced tumors developed in BALB/c and IL-1alpha deficient mice. Glycoconj J. 26:1181-1195.
20. Street, S. E., E. Cretney, and M. J. Smyth. 2001. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97:192-197.
21. Waldhauer, I., and A. Steinle. 2008. NK cells and cancer immunosurveillance. Oncogene 27:5932-5943.
22. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9:495-502.
23. Raulet, D. H. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3:781-790.
24. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107:159-166.
25. Jamieson, A. M., A. Diefenbach, C. W. McMahon, N. Xiong, J. R. Carlyle, and D. H. Raulet. 2002. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19-29.
26. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. Oncogene 27:5944-5958.
27. Horai, R., M. Asano, K. Sudo, H. Kanuka, M. Suzuki, M. Nishihara, M. Takahashi, and Y. Iwakura. 1998. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187:1463-1475.
28. Krelin, Y., E. Voronov, S. Dotan, M. Elkabets, E. Reich, M. Fogel, M. Huszar, Y. Iwakura, S. Segal, C. A. Dinarello, and R. N. Apte. 2007. Interleukin-1betadriven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 67:1062-1071.
29. Mahabeleshwar, G. H., P. R. Somanath, and T. V. Byzova. 2006. Methods for isolation of endothelial and smooth muscle cells and in vitro proliferation assays. Methods Mol. Med. 129:197-208.
30. Kuczek, T., and D. E. Axelrod. 1987. Tumor cell heterogeneity: divided-colony assay for measuring drug response. Proc. Natl. Acad. Sci. USA 84:4490-4494.
31. Cerwenka, A., A. B. Bakker, T. McClanahan, J. Wagner, J. Wu, J. H. Phillips, and L. L. Lanier. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12:721-727.
32. Mori, N., Y. Yamashita, T. Tsuzuki, A. Nakayama, M. Nakazawa, Y. Hasegawa, H. Kojima, and T. Nagasawa. 2000. Lymphomatous features of aggressive NK cell leukaemia/lymphoma with massive necrosis, haemophagocytosis and EB virus infection. Histopathology 37:363-371.
33. Song, X., Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte. 2005. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 175:8200-8208.
34. Gazit, R., R. Gruda, M. Elboim, T. I. Arnon, G. Katz, H. Achdout, J. Hanna, U. Qimron, G. Landau, E. Greenbaum, et al. 2006. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7:517-523.
35. Lecoeur, H., M. Février, S. Garcia, Y. Rivière, and M. L. Gougeon. 2001. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J. Immunol. Methods 253:177-187.
36. Gubbels, J. A., M. Felder, S. Horibata, J. A. Belisle, A. Kapur, H. Holden, S. Petrie, M. Migneault, C. Rancourt, J. P. Connor, and M. S. Patankar. 2010. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer 9:11.
37. Dall'Olio, F., and M. Chiricolo. 2001. Sialyltransferases in cancer. Glycoconj. J. 18:841-850.
38. Yogeeswaran, G., A. Gronberg, M. Hansson, T. Dalianis, R. Kiessling, and R. M. Welsh. 1981. Correlation of glycosphingolipids and sialic acid in YAC-1 lymphoma variants with their sensitivity to natural killer-cell-mediated lysis. Int. J. Cancer 28:517-526.
39. Rughetti, A., I. Pellicciotta, M. Biffoni, M. Bäckström, T. Link, E. P. Bennet, H. Clausen, T. Noll, G. C. Hansson, J. M. Burchell, et al. 2005. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J. Immunol. 174:7764-7772.
40. Nicoll, G., T. Avril, K. Lock, K. Furukawa, N. Bovin, and P. R. Crocker. 2003. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and-independent mechanisms. Eur. J. Immunol. 33:1642-1648.
41. Caldwell, S., A. Heitger, W. Shen, Y. Liu, B. Taylor, and S. Ladisch. 2003. Mechanisms of ganglioside inhibition of APC function. J. Immunol. 171:1676-1683.
42. Andoniou, C. E., J. D. Coudert, and M. A. Degli-Esposti. 2008. Killers and beyond: NK-cell-mediated control of immune responses. Eur. J. Immunol. 38:2938-2942.
43. Mocikat, R., H. Braumüller, A. Gumy, O. Egeter, H. Ziegler, U. Reusch, A. Bubeck, J. Louis, R. Mailhammer, G. Riethmüller, et al. 2003. Natural killer cells activated by MHC class I (low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19:561-569.
44. Hori, K., E. Mihich, and M. J. Ehrke. 1989. Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res. 49:2606-2614.
45. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. M. Greenberg, N. M. Greenberg, and D. H. Raulet. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28:571-580.
46. Hayakawa, Y., and M. J. Smyth. 2006. Innate immune recognition and suppression of tumors. Adv. Cancer Res. 95:293-322.
47. Lanier, L. L. 2005. NKG2D in innate and adaptive immunity. Adv. Exp. Med. Biol. 560:51-56.
48. Floutsis, G., L. Ulsh, and S. Ladisch. 1989. Immunosuppressive activity of human neuroblastoma tumor gangliosides. Int. J. Cancer 43:6-9.
49. Imaizumi, Y., K. Higai, C. Suzuki, Y. Azuma, and K. Matsumoto. 2009. NKG2D and CD94 bind to multimeric alpha2, 3-linked N-acetylneuraminic acid. Biochem. Biophys. Res. Commun. 382:604-608.
50. O'Callaghan, C. A., A. Cerwenka, B. E. Willcox, L. L. Lanier, and P. J. Bjorkman. 2001. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 15:201-211.